Non-segmental Vitiligo
27
11
13
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
11.1%
3 terminated out of 27 trials
72.7%
-13.8% vs benchmark
37%
10 trials in Phase 3/4
75%
6 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (27)
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China
Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients